DSM Biomedical, part of dsm-firmenich, announces it has filed a patent infringement lawsuit against Honeywell following alleged unlawful use of patented technologies in the production and use of Honeywell’s Spectra® MG Bio Blue fibers.
In addition to claiming financial compensation for past and ongoing infringement, DSM Biomedical is asking the federal court in the District of Delaware (Case # 23-675) to order that Honeywell cease manufacturing, marketing, and selling Spectra® MG Bio Blue fibers in the United States (US). DSM Biomedical is a world leading manufacturer of colored Ultra High Molecular Weight Polyethylene (UHMWPE) fibers for the medical industry with a proven track record of success in producing fibers that meet the highest quality, purity, and consistency requirements globally.
Also Read: Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program
“It is well-known that we invest significantly in our R&D to provide DSM Biomedical customers with the most unique biomaterials available within the global medical device market,” said John Witkowski, President at DSM Biomedical. “Our UHMWPE fiber innovations are no exception, which is why we vigilantly protect our solutions with patents. As the market leader in UHMWPE fibers for medical use, and the first company to produce and market colored UHMWPE medical-grade fibers, our intent is to protect our investments when we discover infringements of our patented technologies. This ensures that our customers are safeguarded from unauthorized uses of our technology.”
DSM Biomedical holds a broad portfolio of patents in various countries around the world and proactively monitors third-party activities for potential infringement, acting where necessary to protect against illegal use of patented technologies, Honeywell.
SOURCE: PRWeb